Product Description
Albiglutide (Tanzeum) is a glucagon-like peptide 1 (GLP-1) receptor agonist labeled as an adjunct to diet and exercise for the management of type 2 diabetes mellitus in adults. As with other GLP-1 receptor agonists, albiglutide stimulates postmeal insulin secretion and slows gastric emptying to promote satiety (Sourced from: https://www.aafp.org/afp/2017/0415/p521.html)
Mechanisms of Action: GLP-1 Agonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Approved
Approved Countries: Brazil | Canada | European Medicines Agency | Hungary | Ireland | Italy | Lithuania | Portugal | Spain | Sweden | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Motion Sickness|Type 2 Diabetes
Phase 3: Respiratory Distress Syndrome, Newborn|Type 2 Diabetes|Kidney Diseases
Phase 2: Type 1 Diabetes|Type 2 Diabetes|Heart Failure
Phase 1: Type 2 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| CER-4-T2D | N/A |
Unknown status |
Kidney Diseases|Type 2 Diabetes |
2024-07-31 |
2024-08-02 |
||
| NCT03015519 | P3 |
Withdrawn |
Type 2 Diabetes |
2020-04-20 |
2019-03-21 |
Treatments |
|
| Harmony Outcomes | P4 |
Completed |
Type 2 Diabetes |
2020-01-29 |
2022-03-13 |
Treatments |
|
| RDMSTEP | N/A |
Completed |
Type 2 Diabetes |
2018-12-01 |
2020-11-13 |
Patient Enrollment|Primary Endpoints|Treatments |
|
| NCT02465515 | P4 |
Completed |
Type 2 Diabetes |
2018-02-20 |
2019-03-20 |
Patient Enrollment|Study Completion Date |
|
| Study 110933 | P2 |
Completed |
Type 1 Diabetes |
2017-10-18 |
2019-03-20 |
||
| Type l DM study | P2 |
Terminated |
Type 1 Diabetes |
2017-10-18 |
2022-03-13 |
Treatments |
|
| NCT02802514 | P4 |
Terminated |
Motion Sickness |
2017-08-10 |
2020-08-25 |
Primary Endpoints |
|
| The Switch Study | P3 |
Completed |
Type 2 Diabetes |
2017-07-24 |
2019-03-20 |
Treatments |
|
| The Switch Study | P3 |
Completed |
Type 2 Diabetes |
2017-07-04 |
2025-06-06 |
Treatments |
|
| NCT02683746 | P3 |
Completed |
Type 2 Diabetes |
2017-04-03 |
2019-03-20 |
Treatments |
|
| NCT02750930 | P4 |
Terminated |
Type 2 Diabetes |
2017-03-21 |
2019-03-22 |
Treatments |
|
| NCT02793154 | P4 |
Terminated |
Type 2 Diabetes |
2017-03-16 |
2019-03-20 |
||
| NCT02660736 | P1 |
Completed |
Type 2 Diabetes |
2016-08-01 |
2019-03-20 |
Treatments |
|
| Study GLP111892 | P3 |
Withdrawn |
Type 2 Diabetes |
2015-12-01 |
2019-03-20 |
Treatments |
|
| NCT02496221 | P4 |
Completed |
Type 2 Diabetes |
2015-10-13 |
2019-03-20 |
Treatments |
|
| 2014-001969-27 | P3 |
Terminated |
Type 2 Diabetes |
2015-06-22 |
2022-03-13 |
Treatments |
|
| NCT01777282 | P3 |
Completed |
Type 2 Diabetes |
2015-01-27 |
2019-03-19 |
||
| NCT01733758 | P3 |
Completed |
Type 2 Diabetes |
2014-06-01 |
2019-03-19 |
Treatments |
|
| 2008-007664-42 | P3 |
Completed |
Type 2 Diabetes |
2013-03-25 |
2022-03-13 |
Treatments |
|
| 2008-007660-41 | P3 |
Completed |
Type 2 Diabetes |
2013-03-21 |
2022-03-13 |
Treatments |
|
| NCT01098539 | P3 |
Completed |
Type 2 Diabetes|Kidney Diseases |
2012-11-01 |
2019-03-19 |
Treatments |
|
| NCT01357889 | P2 |
Completed |
Type 2 Diabetes |
2012-10-01 |
2019-03-19 |
Treatments |
|
| NCT01357850 | P2 |
Completed |
Heart Failure |
2012-09-18 |
2019-03-19 |
Treatments |
|
| 2010-020352-59 | P2 |
Completed |
Heart Failure |
2012-09-18 |
2022-03-13 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
08/06/2024 |
News Article |
Annovis' Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist |
|
09/12/2023 |
News Article |
Glucagon-like peptide 1 (GLP-1)-based Therapies Market 2023 Size, Status and Industry Outlook |
|
08/11/2023 |
News Article |
GI Multi-Society Statement Regarding GLP-1 Agonists and Endoscopy |
|
06/20/2022 |
News Article |
Global Therapeutic Proteins Market Report 2022-2031 Featuring Major Players - Abbott Laboratories; Amgen Inc.; Baxter International Inc.; Eli Lilly and Company; F.Hoffmann-La Roche |